Investigator-led study · Small Molecule · Phase 2
ActiveTherapeutic
Population
Adults · >18 to <80 years
NTM infection receiving intravenous amikacin
Evidence
registry
Confidence
83%
Indications
Hearing LossOtotoxicityAminoglycoside-Induced Hearing Loss